Cargando…

Interferon-γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer

Programmed death-ligand 1 (PD-L1) plays an essential role in tumor cell escape from anti-tumor immunity in various types of cancer, including gastric cancer (GC). The present study investigated the intracellular and membrane-bound expression of PD-L1 in the GC cell lines MKN1, MKN74, KATO III and OC...

Descripción completa

Detalles Bibliográficos
Autores principales: Imai, Yushi, Chiba, Tetsuhiro, Kondo, Takayuki, Kanzaki, Hiroaki, Kanayama, Kengo, Ao, Junjie, Kojima, Ryuta, Kusakabe, Yuko, Nakamura, Masato, Saito, Tomoko, Nakagawa, Ryo, Suzuki, Eiichiro, Nakamoto, Shingo, Muroyama, Ryosuke, Tawada, Akinobu, Matsumura, Tomoaki, Nakagawa, Tomoo, Kato, Jun, Kotani, Ai, Matsubara, Hisahiro, Kato, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400993/
https://www.ncbi.nlm.nih.gov/pubmed/32782533
http://dx.doi.org/10.3892/ol.2020.11757
Descripción
Sumario:Programmed death-ligand 1 (PD-L1) plays an essential role in tumor cell escape from anti-tumor immunity in various types of cancer, including gastric cancer (GC). The present study investigated the intracellular and membrane-bound expression of PD-L1 in the GC cell lines MKN1, MKN74, KATO III and OCUM-1. Furthermore, soluble PD-L1 (sPD-L1) level in the supernatant of GC cells and the serum of patients with GC and healthy controls was determined by ELISA. Interferon (IFN)-γ treatment of cells resulted in increased cytoplasmic expression of PD-L1 in GC cells in a dose-dependent manner, except for MKN74 cells; however, there was no association between tumor necrosis factor-α treatment and enhanced PD-L1 expression. Concordant with these findings, results from flow cytometry analysis demonstrated that membrane-bound PD-L1 expression was also increased following GC cell treatment with IFN-γ in a dose-dependent manner. In addition, significant sPD-L1 overproduction was observed only in the culture supernatant of OCUM-1 cells. Serum level of sPD-L1 was significantly increased in patients with GC, in particular in stage IV patients, compared with healthy controls. In conclusion, the present study demonstrated that IFN-γ treatment increased the intracellular and membrane-bound PD-L1 expression in GC cells. In addition, sPD-L1 was detected not only in the supernatant of GC cells but also in the serum of patients with GC. Further investigation on the underlying mechanism of regulation of PD-L1 expression and sPD-L1 production is required.